<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00807794</url>
  </required_header>
  <id_info>
    <org_study_id>MI-CP027</org_study_id>
    <nct_id>NCT00807794</nct_id>
  </id_info>
  <brief_title>A Safety Clinical Trial of Different Doses of MEDI-507 in the Prevention of Acute Renal Allograft Rejection</brief_title>
  <official_title>Phase I Evaluation of the Pharmacokinetics, Pharmacodynamics and Safety of Different Doses of MEDI-507 in the Prevention of Acute Renal Allograft Rejection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>MedImmune LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>MedImmune LLC</source>
  <brief_summary>
    <textblock>
      To evaluate the clinical safety of different doses of MEDI-507 through day 33.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To evaluate the pharmacokinetic characteristics of MEDI-507 given in dose intervals.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 1997</start_date>
  <completion_date type="Actual">January 1998</completion_date>
  <primary_completion_date type="Actual">November 1997</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate the clinical safety of MEDI-507. Each adverse event will be reported by severity grade, relationship to study drug, organ system, and need for medical intervention.</measure>
    <time_frame>Day 33</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To collect initial pharmacokinetic parameters, the incidence and time to first episode of acute rejection, the number of episodes of rejection and graft survival.</measure>
    <time_frame>Day 33</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">13</enrollment>
  <condition>Kidney Diseases</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MEDI-507</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MEDI-507</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MEDI-507</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MEDI-507</description>
  </arm_group>
  <arm_group>
    <arm_group_label>5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MEDI-507</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MEDI-507</intervention_name>
    <description>0.012 mg/kg dose given twice between 60 to 72 hours apart</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MEDI-507</intervention_name>
    <description>0.06 mg/kg dose given twice between 60 to 72 hours apart</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MEDI-507</intervention_name>
    <description>0.12 mg/kg dose given twice between 60 to 72 hours apart</description>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MEDI-507</intervention_name>
    <description>0.24 mg/kg dose given twice between 60 to 72 hours apart (supplemental)</description>
    <arm_group_label>4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MEDI-507</intervention_name>
    <description>0.50 mg/kg dose given twice between 60 to 72 hours apart (supplemental)</description>
    <arm_group_label>5</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Renal allograft recipients receiving their first or second allograft

          -  Age over 18

          -  Maintained on conventional immunosuppression

          -  Completed informed consent document

        Exclusion Criteria:

          -  Known hypersensitivity to MEDI-507

          -  More than two renal allografts

          -  Moribund and unlikely (in the opinion of the investigator) to survive the duration of
             the trial

          -  Simultaneous use of other investigational agents (this does not include the use of
             licensed agents for indications not listed in the package insert)

          -  Any of the following clinical settings or diagnoses posttransplant:

        pregnancy or nursing mother: Ø Human Immunodeficiency Virus infection Ø hemodialysis or
        chronic peritoneal dialysis Ø use of a ventilator Ø hyperacute rejection

          -  Having received OKT3, tacrolimus, or antilymphocyte globulin during the current
             allograft

          -  Less than 10 ml/hr average urine output over 4 hours since the end of surgery
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>J. Bruce McClain, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>MedImmune LLC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Yale University School of Medicine</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06510</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indiana University</name>
      <address>
        <city>Bloomington</city>
        <state>Indiana</state>
        <zip>47405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>San Antonio Community Hospital</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Virginia</name>
      <address>
        <city>Charlottesville,</city>
        <state>Virginia</state>
        <zip>22908</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 10, 2008</study_first_submitted>
  <study_first_submitted_qc>December 10, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 12, 2008</study_first_posted>
  <last_update_submitted>December 10, 2008</last_update_submitted>
  <last_update_submitted_qc>December 10, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 12, 2008</last_update_posted>
  <responsible_party>
    <name_title>J. Bruce McClain, M.D.</name_title>
    <organization>Medimmune Inc.</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

